Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 11/20 | 1.00 |
| ▸ | ACHE | P22303 | 8/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.63 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | IGF1R | P08069 | 1/20 | 0.63 |
| ▸ | ROS1 | P08922 | 1/20 | 0.63 |
| ▸ | PIM1 | P11309 | 1/20 | 0.63 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.63 |
| ▸ | FER | P16591 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | MARK3 | P27448 | 1/20 | 0.63 |
| ▸ | AXL | P30530 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12732198 | 0.94 | BCHE (0.89) | BCHEACHEPLK4AURKAMAPK13 | |
| SCHEMBL14291953 | 0.89 | BCHE (0.89) | BCHEACHE | |
| SCHEMBL28621381 | 0.89 | BCHE (1.00) | BCHEACHEPLK4AURKAMAPK13 | |
| SCHEMBL22147539 | 0.88 | BCHE (1.00) | BCHEACHEHPGD | |
| SCHEMBL28628271 | 0.86 | BCHE (1.00) | BCHEACHE | |
| SCHEMBL22147536 | 0.86 | BCHE (1.00) | BCHEACHEHPGD | |
| SCHEMBL22147541 | 0.85 | BCHE (0.74) | BCHEACHE | |
| SCHEMBL22147540 | 0.85 | BCHE (0.74) | BCHEACHE | |
| SCHEMBL22147537 | 0.83 | BCHE (0.82) | BCHEACHEHPGD | |
| SCHEMBL22147542 | 0.83 | BCHE (0.71) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114984221-A | Application of PP2A and activator thereof in pharmacy and marking of acute ischemic stroke | 浙江大学 | 2022-09-02 | — | — | CN | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2024182633-A2 | TARGETED DEPHOSPHORYLATION OF TAU | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024077223-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240066006-A1 | Antiviral Compounds and Applications Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-29 | — | — | US | disclosed |
| CN-117045802-A | Application of protein phosphatase PP2A inhibitor and gemcitabine in combination in preparation of antitumor drugs | 中国人民解放军海军军医大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-114984221-A | Application of PP2A and activator thereof in pharmacy and marking of acute ischemic stroke | 浙江大学 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022133494-A1 | ANTIVIRAL COMPOUNDS AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022094615-A1 | COMPOUNDS AND METHODS FOR INCREASED ANTISENSE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220062291-A1 | COMPOSITIONS AND METHODS OF TREATING CANCERS BY ADMINISTERING A PHENOTHIAZINE-RELATED DRUG THAT ACTIVATES PROTEIN PHOSPHATASE 2A (PP2A) WITH REDUCED INHIBITORY ACTIVITY TARGETED TO THE DOPAMINE D2 RECEPTOR AND ACCOMPANYING TOXICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| WO-2020132259-A1 | COMPOSITIONS AND METHODS OF TREATING CANCERS BY ADMINISTERING A PHENOTHIAZINE-RELATED DRUG THAT ACTIVATES PROTEIN PHOSPHATASE 2A (PP2A) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062291-A1 | COMPOSITIONS AND METHODS OF TREATING CANCERS BY ADMINISTERING A PHENOTHIAZINE-RELATED DRUG THAT ACTIVATES PROTEIN PHOSPHATASE 2A (PP2A) WITH REDUCED INHIBITORY ACTIVITY TARGETED TO THE DOPAMINE D2 RECEPTOR AND ACCOMPANYING TOXICITY | PPP2CA, PPP2R2A, PPP3CA | BCHE 4587/4885ACHE 3792/4885PLK4 244/4885 |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | DUSP1, DUSP26, DUSP22 | BCHE 4763/4885ACHE 4424/4885PLK4 1425/4885 |
| US-20240066006-A1 | Antiviral Compounds and Applications Thereof | MAVS, ZC3HAV1, EIF2AK2 | BCHE 1311/4885ACHE 1537/4885PLK4 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.